Aloe
drugOn this page
Also known as Aloe (aloe barbadensis)Aloe barbadensis leafAloe barbadensis leaf juiceAloe barbadensis leaf juice powderAloe barbadensis leaf powderAloe barbadensis leaf waterAloe barbadensis miller leafAloe capensis leafAloe ferox miller leafAloe folium (aloe vera)Aloe herba (aloe vera)Aloe leafAloe leaf inspiccated juiceAloe leaf juiceAloe leaf latexAloe socotrinaAloe veraAloe vera dry leaf juiceAloe vera gel
Summary
Aloe (CHEMBL2108221) is a phase-3 clinical-stage unknown; indicated across 8 conditions including radiodermatitis and periodontitis.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 8 conditions
- Clinical trials: 21
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108221 |
| Name | Aloe |
| Type | Unknown |
| Max phase | 3 |
Also known as: Aloe, Aloe (aloe barbadensis), Aloe barbadensis leaf, Aloe barbadensis leaf juice, Aloe barbadensis leaf juice powder, Aloe barbadensis leaf powder, Aloe barbadensis leaf water, Aloe barbadensis miller leaf, Aloe capensis leaf, Aloe ferox miller leaf, Aloe folium (aloe vera), Aloe herba (aloe vera)
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| radiodermatitis | 3 | MONDO:0043771 | MONDO:0043771 |
| periodontitis | 2 | MONDO:0005076 | EFO:0000649 |
| dental caries | 2 | MONDO:0005276 | EFO:0003819 |
| periodontal disorder | 2 | MONDO:0002635 | MONDO:0002635 |
| gingivitis | 2 | MONDO:0002508 | MONDO:0002508 |
| injury | 1 | MONDO:0021178 | EFO:0000546 |
| interstitial cystitis | 0 | MONDO:0018301 | EFO:0008507 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 21.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 10 |
| PHASE4 | 4 |
| PHASE2/PHASE3 | 3 |
| PHASE1/PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06266494 | PHASE4 | RECRUITING | Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis |
| NCT00219466 | PHASE4 | COMPLETED | Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash |
| NCT02437747 | PHASE4 | COMPLETED | Locally Delivered Aloe Vera Gel in the Treatment of Chronic Periodontitis Patients With Diabetes Mellitus |
| NCT06879366 | PHASE4 | COMPLETED | Evaluation of the Efficacy of Aloe-Vera el Versus Bezydamine Hydrochloride in the Prevention of Radiation Induced Oral Mucositis A Randamized Controlled Clinical Trial |
| NCT00876642 | PHASE3 | COMPLETED | Trial Comparing Best Supportive Care to Aloe Vera Gel |
| NCT02386020 | PHASE2/PHASE3 | COMPLETED | Aloe Vera in Chronic Periodontitis With Type 2 Diabetes Mellitus |
| NCT02462993 | PHASE2/PHASE3 | COMPLETED | Local Drug Delivery of Aloe Vera Gel in Chronic Periodontitis |
| NCT03204097 | PHASE2/PHASE3 | COMPLETED | Local Host Modulating Agents Alendronate & Aloe Vera for Treatment of Furcation Defects in Chronic Periodontitis |
| NCT07346677 | PHASE2 | NOT_YET_RECRUITING | Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel |
| NCT02819817 | PHASE1/PHASE2 | WITHDRAWN | A Trial of Topical Aloe Vera Gel in Emergency Department Patients Presenting With Simple Traumatic Wounds |
| NCT06862817 | PHASE1/PHASE2 | COMPLETED | Comparison Between the Effect of Aloe Vera and Benzydamine Hydrochloride Mouth Gel on Prevention of Pain and Progression of Radiation-induced Oral Mucositis |
| NCT05223127 | Not specified | NOT_YET_RECRUITING | Aloe Vera on Caesarean Section Wound |
| NCT06984848 | Not specified | RECRUITING | Effect of Enzymatic-Containing Mouth Spray (Oral7®) on Xerostomia Symptoms, Salivary Flow Rate, and Oral Health-Related Quality of Life in Older Patients |
| NCT00498992 | Not specified | UNKNOWN | Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer |
| NCT02404701 | Not specified | COMPLETED | Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk |
| NCT03493984 | Not specified | WITHDRAWN | Plant Exosomes and Patients Diagnosed With Polycystic Ovary Syndrome (PCOS) 17 |
| NCT04753775 | Not specified | COMPLETED | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ENEMA ALOE VERA GEL IN ACTIVE ULCERATIVE PROCTOSIGMOIDITIS. |
| NCT04942470 | Not specified | COMPLETED | Effect of Aloe Vera and Propolis on Wound Healing in Pressure Injuries |
| NCT05327049 | Not specified | COMPLETED | Evaluation of the Remineralizing Effect of Aloe Vera Versus Diode Laser for Management of Deep Carious Lesions. |
| NCT06243601 | Not specified | COMPLETED | Effect of Aloe Vera Gel as an Intra Canal Medicament |
| NCT06377657 | Not specified | COMPLETED | Oxidative and Antioxidant Indices to HIIT and Aloe Vera Supplementation in Patients With T2DM |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: radiodermatitis